Health News
FDA calculates costs of lost enjoyment if e-cigarette rules prevent smoking
NEW YORK - As U.S. health regulators consider what rules to impose on electronic cigarettes, in their tally of costs and benefits they have placed a value on the lost pleasure consumers may suffer if they used the products less or not at all.
Roche acquires DNA sequencing firm for up to $350 million
ZURICH - Swiss drugmaker Roche said it was buying privately held U.S. gene-sequencing firm Genia Technologies for up to $350 million, securing access to a technology that should allow it to decipher human genes at a cheaper cost.
Malaysia says Cadbury products found not to contain pig DNA
KUALA LUMPUR - New tests conducted by Malaysian authorities found that chocolate bars made by British confectioner Cadbury do not contain pig DNA, contrary to a previous finding, the country's Islamic affairs agency said on Monday.
GSK in $350 million deal to develop cancer drugs with UK biotech firm
- GlaxoSmithKline Plc GSK.L has agreed a deal worth more than $350 million with British biotech company Adaptimmune to develop cancer drugs based on novel cell-based therapies.
Saudi Arabia tests Cadbury chocolates for pork traces
RIYADH - Saudi Arabian authorities said on Saturday they are testing chocolate bars made by British confectioner Cadbury for traces of pork DNA after two of its products in Malaysia were found to violate Islamic standards.
U.S. to test immunotherapy drugs on newly diagnosed brain tumors
CHICAGO - U.S. researchers are finalizing plans to test two immunotherapy drugs made by Bristol-Myers Squibb Co on patients newly diagnosed with the most common form of deadly brain tumors in adults.
Novartis skin cancer drug shrinks tumors in Phase II trial
ZURICH - An experimental drug from Novartis markedly shrank tumors in patients with advanced basal cell carcinoma, the most common form of skin cancer, according to the results of a mid-stage study published on Sunday.
FDA cancer chief says 'escalating' drug prices can't continue
CHICAGO - By law, Dr. Richard Pazdur, the U.S. Food and Drug Administration's cancer drug czar, is not allowed to consider the cost of treatments his agency reviews, only whether they are safe and effective.
Study may open new options for younger women with breast cancer
CHICAGO - The estrogen-blocking drug Aromasin worked better than the long-standing therapy tamoxifen at keeping cancers from returning in younger women with early stage breast cancer, a finding that may change the way the patients are treated, U.S. researchers said on Sunday.
E-cigarettes could sweeten potential Reynolds-Lorillard deal
NEW YORK - When Lorillard Inc bought the blu eCigs brand two years ago, the electronic cigarette had a 10 percent share of a tiny U.S. market, generating about $50 million in sales. It was available in only 12,000 retail outlets and over the Internet.
Video: Health Reform Watch
Cancer in Context
A series that looks at all facets of cancer, written by Debra Sherman, a lung cancer patient who succumbed to the disease on April 22, 2014. Debra covered the health beat for Reuters for more than a decade and drew on her knowledge about health, her contacts in the industry and her personal experiences to report this series. Full Article
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
